1. Home
  2. ALLO vs HTBK Comparison

ALLO vs HTBK Comparison

Compare ALLO & HTBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALLO
  • HTBK
  • Stock Information
  • Founded
  • ALLO 2017
  • HTBK 1997
  • Country
  • ALLO United States
  • HTBK United States
  • Employees
  • ALLO N/A
  • HTBK N/A
  • Industry
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • HTBK Major Banks
  • Sector
  • ALLO Health Care
  • HTBK Finance
  • Exchange
  • ALLO Nasdaq
  • HTBK Nasdaq
  • Market Cap
  • ALLO 438.2M
  • HTBK 566.4M
  • IPO Year
  • ALLO 2018
  • HTBK 1998
  • Fundamental
  • Price
  • ALLO $1.92
  • HTBK $9.02
  • Analyst Decision
  • ALLO Strong Buy
  • HTBK Buy
  • Analyst Count
  • ALLO 10
  • HTBK 2
  • Target Price
  • ALLO $10.06
  • HTBK $11.75
  • AVG Volume (30 Days)
  • ALLO 3.0M
  • HTBK 314.7K
  • Earning Date
  • ALLO 11-07-2024
  • HTBK 01-23-2025
  • Dividend Yield
  • ALLO N/A
  • HTBK 5.83%
  • EPS Growth
  • ALLO N/A
  • HTBK N/A
  • EPS
  • ALLO N/A
  • HTBK 0.71
  • Revenue
  • ALLO $43,000.00
  • HTBK $169,172,000.00
  • Revenue This Year
  • ALLO N/A
  • HTBK N/A
  • Revenue Next Year
  • ALLO N/A
  • HTBK $5.68
  • P/E Ratio
  • ALLO N/A
  • HTBK $12.74
  • Revenue Growth
  • ALLO 26.47
  • HTBK N/A
  • 52 Week Low
  • ALLO $1.78
  • HTBK $7.66
  • 52 Week High
  • ALLO $5.78
  • HTBK $11.27
  • Technical
  • Relative Strength Index (RSI)
  • ALLO 39.98
  • HTBK 31.54
  • Support Level
  • ALLO $2.11
  • HTBK $8.62
  • Resistance Level
  • ALLO $2.40
  • HTBK $9.52
  • Average True Range (ATR)
  • ALLO 0.17
  • HTBK 0.25
  • MACD
  • ALLO 0.00
  • HTBK -0.04
  • Stochastic Oscillator
  • ALLO 15.79
  • HTBK 30.08

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.

About HTBK Heritage Commerce Corp

Heritage Commerce Corp operates as a bank holding company. The company, through its subsidiary, offers commercial banking services to small and medium-sized businesses and their owners, managers, and employees. It operates through two segments, namely Banking and Factoring. The bank generates its revenue from the Banking segment.

Share on Social Networks: